SynthesisInternational urology and nephrology2026
Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis.
Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gallbladder large cell neuroendocrine carcinoma in a patient with multiple myeloma: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study synthesizes previous studies to investigate the risk of second primary cancer (SPC) in patients with renal cell carcinoma (RCC) compared with the general population.
methodsFollowing the PRISMA guidelines, four databases were searched for relevant articles without date limits. Studies were included if they reported the standardized incidence ratio (SIR) for SPCs in patients with RCC compared with the general population. Random-effects model employing the Der Simonian and Laird method was used to pool the SIR by SPC sites. Effect heterogeneity was assessed using I
resultsTwenty-seven retrospective cohort studies published between 1993 and 2024 were included in the study. The overall risk of developing any SPCs was higher among RCC patients (pooled SIR = 1.32, CI 1.19-1.48). The risk of several SPCs was significantly higher in patients with RCC compared with the general population, including cancers of the contralateral kidney (3.68, CI 1.85-7.24), thyroid (3.05, CI 2.57-3.62), urinary bladder (2.15, CI 1.40-3.30), small intestine (1.98, CI 1.01-3.91), leukemia (1.86, CI 1.28-2.70), pancreas (1.64, CI 1.22-2.19), NH lymphoma (1.55, CI 1.21-1.98), melanoma (1.47, CI 1.15-1.88), prostate (1.44, CI 1.21-1.71), and colorectal (1.25, CI 1.10-1.43), bone (2.31, CI 1.25-4.27), endocrine system (4.33, CI 3.28-5.74) and brain/nervous system (2.20, CI 1.25-3.88).
conclusionPatients with RCC have an increased risk of SPCs compared with the general population. These findings highlight the need to develop strategies for the management of SPCs in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.